Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin.
Sera from 106 blood donors, 40 patients with primary immunodeficiencies (ID) treated with gamma-globulin, and 46 patients with selective IgA deficiency were analyzed by an enzyme-linked immunosorbent assay for anti-IgA antibodies. Increased levels of antibodies to IgA were found in 5.6% of the blood donors, 17.5% of the ID patients, and 36.8% of the isolated IgA deficiencies. The percentage was higher in patients with IgA and IgG2 deficiencies (50%). The percentage of patients having increased levels of anti-IgA antibodies was similar to the total prevalence of the 10 other autoantibodies studied. These anti-IgA antibodies were mainly of the IgG class, except from one blood donor with IgM antibodies, and two patients, one with isolated IgA deficiency and the other with common variable immunodeficiency who had anti-IgA antibodies of the IgE class. The latter patient developed a near fatal anaphylactic reaction when intravenous gamma-globulin was administered. Most of the patients with severe adverse reactions to gamma-globulin did not present anti-IgA antibodies. Our data suggest that at least in some immunodeficient patients the elevated amounts of anti-IgA antibodies are not related to the administration of exogenous IgA. The importance of measuring anti-IgA antibodies of the IgG and IgE isotypes in IgA-deficient patients as well as in patients in treatment with gamma-globulin is emphasized.
D000328:Adult; D000361:Agammaglobulinemia / Q000276:immunology* / Q000628:therapy; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology* / Q000628:therapy; D005719:gamma-Globulins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D000888:Antibodies, Anti-Idiotypic; D007070:Immunoglobulin A; D005719:gamma-Globulins